Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3754822 | 1.00 | DPP4 (0.39) | DPP4DPP9DPP7DPP8HRH4 | |
| SCHEMBL3754831 | 1.00 | DPP4 (0.39) | DPP4DPP9DPP7DPP8HRH4 | |
| SCHEMBL3753373 | 0.88 | DPP4 (0.43) | DPP4DPP9DPP7DPP8 | |
| SCHEMBL3753372 | 0.88 | DPP4 (0.43) | DPP4DPP9DPP7DPP8 | |
| SCHEMBL3753374 | 0.88 | DPP4 (0.43) | DPP4DPP9DPP7DPP8 | |
| SCHEMBL3745318 | 0.86 | DPP4 (0.47) | DPP4DPP9DPP7DPP8 | |
| SCHEMBL3745320 | 0.86 | DPP4 (0.47) | DPP4DPP9DPP7DPP8 | |
| SCHEMBL3745322 | 0.86 | DPP4 (0.47) | DPP4DPP9DPP7DPP8 | |
| SCHEMBL3746356 | 0.84 | ALDH1A1 (0.42) | DPP4DPP9DPP7DPP8 | |
| SCHEMBL3746350 | 0.84 | ALDH1A1 (0.42) | DPP4DPP9DPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919854-B1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBVIE INC (US) | 2013-09-18 | — | — | EP | claimed |
| US-7834012-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | claimed |
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2007-03-01 | — | — | US | claimed |
| EP-1919854-B1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBVIE INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-7834012-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049596-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | DPP4 1/4885DPP9 4/4885DPP7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.